Status and phase
Conditions
Treatments
About
The purpose of this study is to determine the best way to administer the candidate HIV vaccine, ALVAC HIV-1 (vCP205).
Full description
Healthy adult volunteers are assigned randomly to either a vaccine or placebo group. Injections are received either intramuscularly, intradermally, or by delivery under the skin of the volunteer's own white blood cells which have had dendritic cell reinfusion. Volunteers are vaccinated at 0, 1, 3, and 6 month time points. Volunteers are closely monitored for 1 hour after vaccination and keep a diary of symptoms for 1 week post-immunization. Volunteers undergo leukopheresis at the start of the study and after the last vaccination at Walter Reed Army Medical Center. Volunteers receive compensation benefits.
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Inclusion Criteria
Volunteers may be eligible for this study if they:
Exclusion Criteria
Volunteers will not be eligible for this study if they:
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal